HUE045936T2 - Clostridium difficile immunogén készítmény - Google Patents

Clostridium difficile immunogén készítmény

Info

Publication number
HUE045936T2
HUE045936T2 HUE15733404A HUE15733404A HUE045936T2 HU E045936 T2 HUE045936 T2 HU E045936T2 HU E15733404 A HUE15733404 A HU E15733404A HU E15733404 A HUE15733404 A HU E15733404A HU E045936 T2 HUE045936 T2 HU E045936T2
Authority
HU
Hungary
Prior art keywords
immunogenic composition
clostridium difficile
difficile immunogenic
clostridium
composition
Prior art date
Application number
HUE15733404A
Other languages
English (en)
Inventor
Cindy Castado
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1411306.2A external-priority patent/GB201411306D0/en
Priority claimed from GB201411371A external-priority patent/GB201411371D0/en
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of HUE045936T2 publication Critical patent/HUE045936T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HUE15733404A 2014-06-25 2015-06-25 Clostridium difficile immunogén készítmény HUE045936T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1411306.2A GB201411306D0 (en) 2014-06-25 2014-06-25 Immunogenic composition
GB201411371A GB201411371D0 (en) 2014-06-26 2014-06-26 Immunogenic composition

Publications (1)

Publication Number Publication Date
HUE045936T2 true HUE045936T2 (hu) 2020-01-28

Family

ID=53498986

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE15733404A HUE045936T2 (hu) 2014-06-25 2015-06-25 Clostridium difficile immunogén készítmény

Country Status (18)

Country Link
US (1) US20170218031A1 (hu)
EP (2) EP3160500B1 (hu)
JP (2) JP6688233B2 (hu)
CN (1) CN106536544B (hu)
BE (1) BE1022949B1 (hu)
BR (1) BR112016030096B1 (hu)
CA (1) CA2952118A1 (hu)
CY (1) CY1122145T1 (hu)
DK (1) DK3160500T3 (hu)
ES (1) ES2749701T3 (hu)
HR (1) HRP20191864T1 (hu)
HU (1) HUE045936T2 (hu)
LT (1) LT3160500T (hu)
MX (1) MX2016017094A (hu)
PL (1) PL3160500T3 (hu)
PT (1) PT3160500T (hu)
SI (1) SI3160500T1 (hu)
WO (1) WO2015197737A1 (hu)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3595709A4 (en) * 2017-03-15 2020-12-23 Novavax, Inc. METHODS AND COMPOSITIONS FOR INDUCING IMMUNE RESPONSES TO CLOSTRIDIUM DIFFICILE
CN112703006A (zh) 2018-06-19 2021-04-23 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
GB202205833D0 (en) 2022-04-21 2022-06-08 Glaxosmithkline Biologicals Sa Bacteriophage

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
EP0362278A4 (en) 1987-06-05 1990-05-14 Us Health FACTORS OF AUTOCRINE MOTILITY IN THE DIAGNOSIS AND TREATMENT OF CANCER.
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
ATE115862T1 (de) 1989-02-04 1995-01-15 Akzo Nobel Nv Tocole als impfstoffadjuvans.
PL170980B1 (pl) 1992-06-25 1997-02-28 Smithkline Beecham Biolog Szczepionka PL PL PL PL PL PL PL
ES2162139T5 (es) 1993-03-23 2008-05-16 Smithkline Beecham Biologicals S.A. Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado.
NZ295998A (en) 1994-10-24 1999-10-28 Ophidian Pharm Inc Neutralizing antitoxins against clostridium difficile and clostidium botulinum toxins
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
EP0832282A1 (en) 1995-06-02 1998-04-01 Incyte Pharmaceuticals, Inc. IMPROVED METHOD FOR OBTAINING FULL-LENGTH cDNA SEQUENCES
JP2002542169A (ja) * 1999-04-09 2002-12-10 テクラブ， インコーポレイテッド Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅに対する、組換え毒素Ａ／毒素Ｂワクチン
US20020065396A1 (en) 2000-03-28 2002-05-30 Fei Yang Compositions and methods of diagnosing, monitoring, staging, imaging and treating colon cancer
WO2005004791A2 (en) * 2002-11-08 2005-01-20 President And Fellows Of Harvard College Compounds and methods for the treatment and prevention of bacterial infection
AU2012349753A1 (en) * 2011-12-08 2014-06-19 Novartis Ag Clostridium difficile toxin-based vaccine
AR089797A1 (es) 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
SI2928489T1 (sl) * 2012-12-05 2019-05-31 Glaxosmithkline Biologicals S.A. Imunogeni sestavek
GB201223342D0 (en) * 2012-12-23 2013-02-06 Glaxosmithkline Biolog Sa Immunogenic composition

Also Published As

Publication number Publication date
BE1022949B1 (fr) 2016-10-21
JP6688233B2 (ja) 2020-04-28
CA2952118A1 (en) 2015-12-30
PL3160500T3 (pl) 2020-02-28
EP3160500A1 (en) 2017-05-03
BE1022949A1 (fr) 2016-10-21
ES2749701T3 (es) 2020-03-23
BR112016030096A2 (pt) 2017-08-22
EP3636278A2 (en) 2020-04-15
EP3160500B1 (en) 2019-08-21
MX2016017094A (es) 2017-05-03
WO2015197737A1 (en) 2015-12-30
US20170218031A1 (en) 2017-08-03
LT3160500T (lt) 2019-10-25
HRP20191864T1 (hr) 2020-01-10
JP2020100625A (ja) 2020-07-02
PT3160500T (pt) 2019-11-11
CN106536544A (zh) 2017-03-22
CN106536544B (zh) 2020-04-07
JP2017520573A (ja) 2017-07-27
BR112016030096A8 (pt) 2021-07-06
EP3636278A3 (en) 2020-07-15
DK3160500T3 (da) 2019-11-11
CY1122145T1 (el) 2020-11-25
SI3160500T1 (sl) 2019-11-29
BR112016030096B1 (pt) 2023-10-03

Similar Documents

Publication Publication Date Title
ZA201702401B (en) Composition with reduced immunogenicity
IL248223B (en) Compositions of vaccine
GB201410905D0 (en) Composition
GB201501859D0 (en) Composition
IL251479B (en) components
GB201408167D0 (en) Compositions
GB201403017D0 (en) Composition
HK1243341A1 (zh) 起泡減少的疫苗組合物
GB201414910D0 (en) Composition
GB201403561D0 (en) Composition
PL3160500T3 (pl) Immunogenna kompozycja clostridium difficile
GB201420306D0 (en) Compositions
GB201414555D0 (en) Composition
GB201410493D0 (en) Composition
GB201420628D0 (en) Composition
GB201415483D0 (en) Composition
GB201404390D0 (en) Composition
GB201403550D0 (en) Composition
GB201402648D0 (en) Composition
GB201411371D0 (en) Immunogenic composition
GB201411306D0 (en) Immunogenic composition
GB201401883D0 (en) Combination immunogenic compositions
EP3116537A4 (en) Immunogenic compositions
GB201502355D0 (en) Composition
GB201421660D0 (en) Composition